BTIG Research Increases Masimo (NASDAQ:MASI) Price Target to $200.00

Masimo (NASDAQ:MASI) had its target price raised by research analysts at BTIG Research from $198.00 to $200.00 in a note issued to investors on Thursday, MarketBeat reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. BTIG Research’s target price indicates a potential upside of 41.16% from the stock’s previous close.

A number of other equities research analysts have also recently commented on MASI. Piper Sandler raised their target price on shares of Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 6th. Wall Street Zen raised shares of Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Weiss Ratings restated a “sell (d)” rating on shares of Masimo in a research note on Wednesday, October 8th. Bank of America initiated coverage on shares of Masimo in a report on Monday, November 17th. They issued a “neutral” rating and a $162.00 target price for the company. Finally, Wells Fargo & Company decreased their price target on Masimo from $190.00 to $187.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $189.40.

Masimo Price Performance

Shares of Masimo stock opened at $141.68 on Thursday. The stock has a market cap of $7.61 billion, a P/E ratio of -13.44, a P/E/G ratio of 1.65 and a beta of 1.26. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.92 and a current ratio of 2.84. The stock’s fifty day moving average is $145.86 and its 200 day moving average is $151.88. Masimo has a one year low of $133.70 and a one year high of $194.88.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share (EPS) for the quarter. Masimo had a positive return on equity of 33.04% and a negative net margin of 33.20%.The business had revenue of $617.00 million during the quarter. Sell-side analysts anticipate that Masimo will post 4.1 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MASI. Nordea Investment Management AB raised its stake in Masimo by 21.6% during the second quarter. Nordea Investment Management AB now owns 31,868 shares of the medical equipment provider’s stock valued at $5,330,000 after purchasing an additional 5,659 shares in the last quarter. Strs Ohio purchased a new position in shares of Masimo in the 1st quarter worth $6,686,000. Westfield Capital Management Co. LP increased its holdings in shares of Masimo by 75.9% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,181,203 shares of the medical equipment provider’s stock worth $198,702,000 after buying an additional 509,724 shares during the last quarter. Swedbank AB bought a new stake in shares of Masimo in the 1st quarter worth about $12,645,000. Finally, Geode Capital Management LLC raised its position in shares of Masimo by 6.2% during the 2nd quarter. Geode Capital Management LLC now owns 896,418 shares of the medical equipment provider’s stock valued at $150,817,000 after buying an additional 52,100 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.